FibroGen

What FibroGen does

FibroGen, rebranded as Kyntra Bio on January 7, 2026, is a publicly traded (NASDAQ: KYNB) biopharmaceutical company headquartered in San Francisco, founded in 1993. The company develops therapeutics for oncology and rare diseases using two proprietary scientific platforms — connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology — with a current pipeline concentrated on roxadustat (an oral HIF-PH inhibitor for anemia in myelodysplastic syndromes and related indications) and FG-3246 + FG-3180 (a combination oncology candidate targeting prostate cancer). Roxadustat received FDA Orphan Drug Designation for MDS in December 2025, with a Phase 3 protocol targeted for FDA submission in Q4 2025, and the FG-3246 + FG-3180 combination generated positive data from an investigator-sponsored Phase 1b/2 study reported in February 2026.

The company's revenue model has historically combined product and partnership economics. Roxadustat is approved and commercialized in certain non-U.S. markets (notably China via a prior AstraZeneca partnership), generating manufacturing/royalty revenue historically, while U.S. commercialization of an MDS indication remains pending. In 2025 the company executed a strategic transaction to sell FibroGen China to AstraZeneca for approximately $220 million, recorded as a non-recurring gain used to repay an existing term loan and extend cash runway into 2028; this eliminated the China royalty stream but funded the U.S. and global Phase 3 program. Go-to-market is enterprise field sales: upon approval, distribution would run through pharmaceutical wholesalers and specialty pharmacies with field representatives targeting hospitals, oncology centers, and specialty clinics.

Capital structure is supported by a $150 million non-dilutive loan facility from Morgan Stanley Tactical Value (May 2023, three-tranche disbursement) and the AstraZeneca divestiture proceeds, with operational scale of 101-250 employees focused on R&D, clinical development, regulatory, and pre-commercial functions. Customer segments are end-patients with MDS-related anemia and advanced/metastatic prostate cancer, reached indirectly through healthcare providers; no third-party payer or provider logos are disclosed. Management includes Thane Wettig (interim CEO), David DeLucia (CFO), John Hunter (CSO), and Michael D. Lowenstein (Chief Legal Officer & Corporate Secretary), with a Vice President-level bench across preclinical/CMC, regulatory affairs, IP, technical development, and HR.

Name

FibroGen

Legal name

FibroGen, Inc.

Website

https://fibrogen.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Kyntra Bio (formerly FibroGen), a NASDAQ-listed biopharma founded in 1993, develops oral HIF-PH inhibitor roxadustat for MDS-related anemia and the FG-3246 + FG-3180 combination for prostate cancer, targeting patients with high-unmet-need oncology and rare-disease indications.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAIAE

Rare Immunology, Autoimmune & Autoinflammatory Therapies

Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

SECONDARYHLAIACAB

Immunology & Autoimmune Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Biopharmaceutical drug development
• Oncology rare disease therapies
• Anemia treatment drugs
• Clinical stage oncology pipeline
• HIF-PH inhibitor therapeutics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from commercialization of approved drug products including roxadustat for anemia indications and pipeline candidates upon approval. The company previously generated revenue through partnership arrangements including sale of FibroGen China to AstraZeneca for approximately $220 million.
2. Strategic Asset Divestment: Non-recurring revenue from sale of regional assets including FibroGen China subsidiary to AstraZeneca, used to extend cash runway and fund ongoing clinical development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

FibroGen, rebranded as Kyntra Bio in January 2026, is a clinical-stage and commercial biopharmaceutical company developing therapies for oncology and rare diseases. Its lead asset is roxadustat, an oral HIF-PH inhibitor for anemia in myelodysplastic syndromes (MDS) and renal anemia, supplemented by the FG-3246 + FG-3180 combination for prostate cancer and other solid tumors. The company previously developed pamrevlumab, a monoclonal antibody, supported by a $150 million non-dilutive loan facility.

Product overview

FibroGen, rebranded as Kyntra Bio in January 2026, is a biopharmaceutical company developing a pipeline of therapies for oncology and rare diseases. The core portfolio includes Roxadustat (an oral HIF-PH inhibitor for anemia and MDS), FG-3246 and FG-3180 (combination oncology therapies for prostate cancer), and previously pamrevlumab. The company transitioned from a diversified approach to focused development following the sale of FibroGen China to AstraZeneca in 2025.

Differentiator

Problem solved

Functional benefit

Brands

• Roxadustat: HIF-PH inhibitor for treatment of anemia and myelodysplastic syndromes
• FG-3246
• FG-3180

Products and services

• Roxadustat An oral HIF-PH inhibitor therapy developed for anemia across multiple indications including myelodysplastic syndromes (MDS) and renal anemia; first drug in the HIF-PH inhibitor class, differentiated by oral administration versus injectable or infusion-based second-line MDS treatments.
• FG-3246 Oncology therapy in development for prostate cancer and other solid tumors, typically combined with FG-3180 as a combination regimen; subject of investigator-sponsored Phase 1b/2 studies.
• FG-3180

Quantifiable outcome

• Less than 50% of MDS patients achieve transfusion independence with current first-line treatments, creating opportunity for roxadustat differentiation
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Bristol-Myers Squibb: Acquired Acceleron Pharma and commercializes Reblozyl (luspatercept), the leading approved therapy for MDS-related anemia - directly competing with roxadustat. BMY also has a broader oncology and rare disease portfolio overlapping with Kyntra Bio's pipeline.
• AstraZeneca: Acquired FibroGen China subsidiary for $220M and historically partnered with FibroGen on roxadustat development. A major oncology player with overlapping prostate cancer and rare disease pipeline interests.
• Astellas Pharma: Historical roxadustat development partner for Japan and other Asian markets. Major oncology and specialty pharma player with overlapping therapeutic areas to Kyntra Bio's pipeline.
• Takeda Pharmaceutical: Global biopharma with significant rare disease and oncology franchises (post-Shire acquisition). Competes in similar therapeutic categories and has the scale to potentially partner with or acquire Kyntra Bio assets.
• GSK: Has established MDS franchise via lenalidomide (Revlimid) and broader oncology/specialty pharma presence. Competitor in MDS treatment landscape and potential strategic partner.
• Novartis: Major oncology player with multiple prostate cancer therapies (Pluvicto, etc.) that compete with Kyntra Bio's FG-3246/FG-3180 program. Also has rare disease and hematology franchises.
• Bayer: Has established oncology franchise including prostate cancer therapies (Nubeqa/Xofigo) and broader cardiovascular/hematology portfolio. Strategic competitor in Kyntra Bio's target indications.

Direct peers

• Acceleron Pharma: Developed luspatercept (Reblozyl) for MDS-related anemia and was acquired by Bristol-Myers Squibb. Now part of BMY but remains the most direct therapeutic competitor to roxadustat in the MDS anemia space.
• Geron Corporation: Commercializes imetelstat (Rytelo) for transfusion-dependent MDS, representing a direct competitive threat to roxadustat in the lower-risk MDS segment. Similar small-cap, single-asset-focused biopharma profile.

Emerging players

• Bicycle Therapeutics: Clinical-stage biotech developing novel oncology therapeutics, including programs in prostate cancer. Similar size and stage profile to Kyntra Bio, making it a relevant comparator for small-cap oncology pipeline valuation.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/FibroGenInc
• LinkedInlinkedin.com/company/kyntrabio
• Facebookfacebook.com/FibroGen-Inc-106102409479254

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds10 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FibroGen